Chardan Capital Reiterates Buy on Coya Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Coya Therapeutics (NASDAQ:COYA) and maintained an $11 price target.
July 17, 2023 | 4:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has reiterated its 'Buy' rating on Coya Therapeutics and maintained its price target at $11.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Coya Therapeutics. The maintained price target of $11 suggests that the analyst believes the stock is undervalued at current levels. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100